Article Information
History
- June 14, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Elisa Habermann1,†,
- Lutz Gieselmann2,†,
- Pinkus Tober-Lau3,
- Alexander ten Hagen1,
- Fredrik N Albach1,
- Jan Zernicke1,
- Elvin Ahmadov2,
- Amanthi Nadira Arumahandi de Silva1,
- Leonie Maria Frommert1,
- Jens Klotsche2,
- Florian Kurth3,
- Leif Erik Sander3,
- Gerd Burmester1,
- Florian Klein2,5,6 and
- Robert Biesen1,*
- 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 2Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- 3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 4German Rheumatism Research Center Berlin – a Leibniz Institute (DRFZ), Berlin, Germany
- 5German Center for Infection Research, Partner site Bonn-Cologne, Cologne, Germany
- 6Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
- ↵*Address correspondence and reprint request:
Dr. med. Robert Biesen, Department of Rheumatology and Clinical Immunology, Charité University Hospital, Charitéplatz 1, D-10117 Berlin – Germany, E-mail: Robert.Biesen{at}charite.de
↵† contributed equally
Posted June 14, 2022.
Impaired Neutralization of SARS-CoV-2 Including Omicron Variants after COVID-19 mRNA Booster Immunization under Methotrexate Therapy
